Oral SERDs in ER+/HER2- metastatic breast cancer, an analysis of ESR1 wild type/mutant subgroups
An individual patient data metanalysis suggests that oral SERDs improve progression-free survival in ESR1 mutant subgroup, with no significant benefit in ESR1 wild type patients
Molecular features of high proliferation/low ER-related signaling breast cancers suggest more effective therapeutic strategies
A study from Michelangelo Foundation researchers in collaboration with San Raffaele Hospital offers new insights for the treatment of high proliferation/low ER-signaling breast cancers based on molecular features
New data from Michelangelo Foundation’s NeoTRIP trial discussed during ESMO Congress
No Event-free survival improvement by addition of atezolizumab to neoadjuvant chemotherapy in NeoTRIP study but in a subset of triple negative breast cancer with a newly identified predictor restricted to benefit from the anti-PD-L1 antibody
Sacituzumab govitecan in ER+/HER2- metastatic breast cancer
The phase 3 trial TROPiCS-02 shows that the antibody-drug conjugate is safe and effective in heavily treated metastatic breast cancer with limited treatment options
Breast cancer screening in women age 40-49
A canadian study shows that screening programs for women in their 40s increase breast cancer net survival but not the rate of breast cancer diagnosis
Predictive Factors of Immunotherapy Response in Triple-Negative Breast Cancer
A new study by the Michelangelo Foundation, in collaboration with the CRUK Cambridge Institute, demonstrates that the spatial organization and interaction between tumour cells and various cell types critically influence the effect of immune checkpoint blockade.
Irradiation or no irradiation after surgery in early breast cancer
The effects of omission of radiotherapy after surgery on local or distal recurrence and survival in women with low-risk, hormone receptor–positive early breast cancer
The ALPHABET study on breast cancer is enrolling patients
Enrollment of patients with HER2+ metastatic breast cancer and PIK3CA mutation has been started at IEO, to evaluate the addition of alpelisib to current therapies
Olaparib in BRCA-mutated, HER-2 negative metastatic breast cancer
Olaparib significantly prolonged progression-free survival compared to chemotherapy, particularly in first line patients.
Federated learning to predicting chemotherapy response in triple-negative breast cancer
This multicentric machine learning model improves performance of local models in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.
